Lotus Reports August 2026 Revenue of NT$2,107 Million

Taipei, Taiwan, 10 September 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for August 2026 of NT$2,107 million, representing an increase of 82% YoY, mainly driven by the consolidation of Alvogen. Lotus' year-to-date (YTD) August 2026 revenue reached NT$22,052 million, an increase of 69% compared to the same period last year, continued to be supported by Alvogen as well as strong momentum in the B2B business.

For the first eight months ending August 2026, revenue from the US grew 149% YoY to NT$13,083 million for the period, representing c. 59% of the total consolidated revenue, driven by the consolidation of Alvogen. Lotus’ Asia business remained stable with revenue of NT$7,185 million, representing c.33% of the Group’s total consolidated revenue. Lotus’ B2B business grew 216% YoY to NT$1,784 million, contributing c.8% of total consolidated revenue, supported by key product launches such as Nintedanib in Europe and North America as well as Enzalutamide in Brazil, Canada and South Korea.

*For B2B markets, “launch” refers to the initial product shipment to a partner; in-market launch timing is subject to local commercial arrangements.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness